Benign prostatic enlargement is not associated with diabetes: a population-based study

Abstract

The association between diabetes and benign prostatic hyperplasia remains inconclusive. In this case-control study, we examined the association of diabetes with benign prostatic enlargement (BPE) using the Longitudinal Health Insurance Database 2000 in Taiwan. In total, 20 152 patients with BPE as cases and 20 152 age-matched patients without BPE were included as controls. Conditional logistic regression analyses were performed to calculate the odds ratio (OR) and corresponding 95% CI for having been previously diagnosed with diabetes between cases and controls. We found that of the 40 304 sampled patients, 9492 (23.6%) had a history of diabetes before the index date. This mean age for the sampled patients was 65.9 with a standard deviation of 12.0 years. A Chi-squared test revealed that there was a significant difference in the prevalence of prior diabetes between cases and controls (25.3% vs. 21.8%, p < 0.001). The conditional logistic regression found that the OR of prior diabetes for cases was 1.21 (95% CI = 1.15-1.27) compared with controls. However, after adjusting for geographic region, monthly income, urbanization level, hypertension, coronary heart disease (CHD), hyperlipidemia, tobacco use disorder, and obesity, the association between prior diabetes and BPE did not reach a statistically significant level (OR = 1.03, 95% CI = 0.98-1.08). In addition, it was noteworthy that hypertension (OR = 1.25, 95% CI = 1.20-1.31), CHD (OR = 1.40, 95% CI = 1.32-1.48), and hyperlipidemia (OR = 1.30, 95% CI = 1.24-1.36) were all significantly associated with BPE. We found that men with a diagnosis of diabetes were not significantly associated with BPE after adjusting for patient's sociodemographic characteristics and comorbidities.

The association between metabolic syndrome and lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: evidence based on propensity score matching

“…Our study also found that the participants with low HDL or increased triglyceride levels had a greater likelihood of LUTS/BPH, which further supports an emerging understanding of the dyslipidemia profile in aging Chinese males. Similar results have also been reported in other studies (37,38). Martin et al's results suggest that HDL cholesterol and lower triglycerides contribute to predicting the improvement of LUTS (37).…”

The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea

“…Moreover, various confounding factors such as sleep apnea and medications like diuretics for hypertension may lead to lower urinary tract symptoms [25]. A large population‐based study in an Asian population showed that the significant association between T2DM and BPH was confounded with factors such as hypertension, coronary heart disease, and hyperlipidemia [26]. Among these confounding factors, the clinical studies that included medication adjustments for T2DM were also limited, but metformin in T2DM could affect the prognosis of BPH based on solid evidence from preclinical data [17, 18].…”

Metabolic syndrome and benign prostatic hyperplasia: An update

“… [46] reported that the level of HDL-C was lower, while level of total cholesterol and low density lipoprotein cholesterol (LDL-C) were higher in patients with symptomatic BPH than in controls. In a case-control study performed in Taiwan, China, dyslipidaemia was significantly associated with BPE compared with controls [64] .…”